Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe

SOUTH SAN FRANCISCO, Calif., May 31, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending orphan medicinal product (orphan drug) designation for CB 2679d/ISU304 for the treatment of hemophilia B.